



## **Thryv Therapeutics Inc. to Participate in 34th Piper Sandler Annual Healthcare Conference and in RBC Capital Markets Healthcare Private Company Virtual Conference**

**MONTREAL, Quebec, Canada, November 17, 2022** – Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndromes via SGK1 inhibition and resistant cancers, will participate in a fireside chat and host investor meetings at the upcoming 34th Piper Sandler Annual Healthcare Conference, and will participate in a fireside chat at the upcoming 2022 RBC Capital Markets Healthcare Private Company Conference. Mr. Paul F. Truex will provide a full update on Thryv’s progress to date with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT syndrome, atrial fibrillation and resistant cancers.

- Piper Sandler 34th Annual Healthcare Conference  
Location: New York, NY  
Fireside Chat: Tuesday, November 29th, 2022 at 11:10 a.m. ET  
1x1 Meetings: Tuesday, November 29th, 2022
- RBC Capital Markets Healthcare Private Company Virtual Conference  
Virtual Fireside Chat: Wednesday, December 14th, 2022

### **About Thryv Therapeutics Inc.**

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned pharmaceutical company pioneering a precision medicine approach through the inhibition of Serum and Glucocorticoid induced Kinase (SGK1) to treat Long QT Syndrome, Atrial Fibrillation, and resistant and rare cancers. For more information, visit [www.thryvtrx.com](http://www.thryvtrx.com)

### **Media Inquiries**

[daphne@thryvtrx.com](mailto:daphne@thryvtrx.com) | 514 973 0915